181 related articles for article (PubMed ID: 33614119)
1. Substantia nigra micro-haemorrhage causing ipsilateral unilateral Parkinsonism and abnormal dopamine transporter scan uptake.
Ghoneim A; Pollard C; Tyagi A; Jampana R
BJR Case Rep; 2021 Feb; 7(1):20200118. PubMed ID: 33614119
[TBL] [Abstract][Full Text] [Related]
2. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.
Kraemmer J; Kovacs GG; Perju-Dumbrava L; Pirker S; Traub-Weidinger T; Pirker W
Mov Disord; 2014 Dec; 29(14):1767-73. PubMed ID: 25048738
[TBL] [Abstract][Full Text] [Related]
3. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice.
Ba F; Martin WR
Parkinsonism Relat Disord; 2015 Feb; 21(2):87-94. PubMed ID: 25487733
[TBL] [Abstract][Full Text] [Related]
4. Variability of presynaptic nigrostriatal dopaminergic function and clinical heterogeneity in a dopa-responsive dystonia family with GCH-1 gene mutation.
Lin JJ; Lu CS; Tsai CH
J Neurol; 2018 Mar; 265(3):478-485. PubMed ID: 29290055
[TBL] [Abstract][Full Text] [Related]
5. Chapter 33: the history of movement disorders.
Lanska DJ
Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
[TBL] [Abstract][Full Text] [Related]
6. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
[TBL] [Abstract][Full Text] [Related]
7. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
Booij J; Speelman JD; Horstink MW; Wolters EC
Eur J Nucl Med; 2001 Mar; 28(3):266-72. PubMed ID: 11315592
[TBL] [Abstract][Full Text] [Related]
8. [Nuclear neuroimaging of dopamine transporter in Parkinsonism--role in routine clinical practice].
Cohenpour M; Golan H
Harefuah; 2007 Sep; 146(9):698-702, 733. PubMed ID: 17969308
[TBL] [Abstract][Full Text] [Related]
9. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.
Cummings JL; Henchcliffe C; Schaier S; Simuni T; Waxman A; Kemp P
Brain; 2011 Nov; 134(Pt 11):3146-66. PubMed ID: 21810889
[TBL] [Abstract][Full Text] [Related]
10. The role of SPECT imaging of the dopaminergic system in translational research on Parkinson's disease.
Suwijn SR; de Bruin K; de Bie RM; Booij J
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S184-6. PubMed ID: 24262177
[TBL] [Abstract][Full Text] [Related]
11. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
Jeon B; Kim JM; Jeong JM; Kim KM; Chang YS; Lee DS; Lee MC
J Neurol Neurosurg Psychiatry; 1998 Jul; 65(1):60-4. PubMed ID: 9667562
[TBL] [Abstract][Full Text] [Related]
12. Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease.
Isaias IU; Trujillo P; Summers P; Marotta G; Mainardi L; Pezzoli G; Zecca L; Costa A
Front Aging Neurosci; 2016; 8():196. PubMed ID: 27597825
[TBL] [Abstract][Full Text] [Related]
13. Molecular Imaging of the Dopamine Transporter.
Palermo G; Ceravolo R
Cells; 2019 Aug; 8(8):. PubMed ID: 31405186
[TBL] [Abstract][Full Text] [Related]
14. DAT imaging in drug-induced and psychogenic parkinsonism.
Tolosa E; Coelho M; Gallardo M
Mov Disord; 2003 Oct; 18 Suppl 7():S28-33. PubMed ID: 14531043
[TBL] [Abstract][Full Text] [Related]
15. Degree of dopaminergic degeneration measured by
Lin L; Ye J; Zhang H; Han ZF; Zheng ZH
Neural Regen Res; 2018 Jul; 13(7):1281-1287. PubMed ID: 30028339
[TBL] [Abstract][Full Text] [Related]
16.
Yang HJ; Park SH; Seo M; Weon YC; Kim Y
Neurotoxicology; 2018 Jan; 64():78-84. PubMed ID: 28259768
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced parkinsonism.
Shin HW; Chung SJ
J Clin Neurol; 2012 Mar; 8(1):15-21. PubMed ID: 22523509
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review.
Suwijn SR; van Boheemen CJ; de Haan RJ; Tissingh G; Booij J; de Bie RM
EJNMMI Res; 2015; 5():12. PubMed ID: 25853018
[TBL] [Abstract][Full Text] [Related]
19. SPECT and PET imaging of the dopaminergic system in Parkinson's disease.
Brücke T; Djamshidian S; Bencsits G; Pirker W; Asenbaum S; Podreka I
J Neurol; 2000 Sep; 247 Suppl 4():IV/2-7. PubMed ID: 11199811
[TBL] [Abstract][Full Text] [Related]
20. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.
Caminiti SP; Presotto L; Baroncini D; Garibotto V; Moresco RM; Gianolli L; Volonté MA; Antonini A; Perani D
Neuroimage Clin; 2017; 14():734-740. PubMed ID: 28409113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
